In December 2019 a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as the 2019 novel coronavirus (2019-nCoV) was identified in Wuhan, China, causing a world-wide pandemic. Three coronaviruses, SARS-CoV, MERS-CoV, and SARS-CoV-2 have been identified as being a highly pathogenic for humans, and there is currently no effective antiviral treatment. Therefore, studies are focused on rapid development of vaccines and antiviral drugs to prevent and treat coronavirus infection. There are several potential strategies to pharmacologically fight against the disease (COVID-19), including vaccines, monoclonal antibodies, oligonucleotide-based therapies, peptides, interferon therapies, and small-molecule drugs (Dömling & Gao, 2020). RNA-dependent RNA polymerase (RdRp) is an enzyme that is crucial to life cycle of RNA viruses including coronaviruses (Subissi et al., 2014). RdRp catalyzes the synthesis of viral RNA, thereby playing a central role in the replication and transcription cycle of COVID-19 viruses, possibly in complex with nsp7 and nsp8 (Gao et al., 2020). Therefore, RdRp is a prime target for nucleotide analog antiviral inhibitors, such as remedesivir, for development of new antiviral therapeutics (Wang et al., 2020).
Source:Recombinant protein corresponding to SARS-CoV-2 RNA-Dependent RNA Polymerase, fused to His-Tag at C-terminal, expressed in E. coli.
Molecular Weight:~100kD
Applications:Suitable for use in ELISA. Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:Aliquot to avoid repeated freezing and thawing and store at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
Size：100ug
Source Antigen：Recombinant, E. coli
Grade：Purified
Purity：≥85%
Form：Supplied as a liquid in 50mM sodium phosphate, pH 7.5, 300mM sodium chloride, 150mM imidazole, 1mM DTT, 10% glycerol.
